Figure 2 | Scientific Reports

Figure 2

From: A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer

Figure 2

Effects of KYA1797K on the Wnt/β-catenin and the EGFR-Ras-ERK pathways in KRAS WT and MT NSCLC cell lines. (A) TOPflash reporter and Elk-1 reporter activities were measured after treating KYA1797K for 24 hours. Media for HEK-TOP cells were changed to either L-cell conditioned media (L-CM) or Wnt3a-CM with 1, 5, or 25 μmol/L of KYA1797K treatment (TOPflash). HEK-293 cells were treated with EGF along with indicated dose of KYA1797K for 24 hours (Elk-1). Error bars indicate the SD; n = 3. (B) NCI-H1650 and NCI-H460 cells were treated with 25 μmol/L KYA1797K along with cycloheximide (50 μg/mL) and were harvested at different time points after the treatment. (C,D) NCI-H1650 and NCI-H460 cells were harvested 24 hours after the treatment of 1 μmol/L erlotinib, 5 or 25 μmol/L KYA1797K. Total RNAs were isolated and subjected to the real time reverse transcription-PCR (C) or whole cell extracts were prepared for immunoblot analyses (D). Relative mRNA expression is represented by normalization to DMSO-treated control and is presented as mean ± SD; n = 3 (C).

Back to article page